Table 2.
Univariate analyses of individual clinicopathological factors in GCB and non-GCB groups
| Comparision with risk factors | OS |
PFS |
||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Clinical factors | ||||
| Age (<60 vs ≥60 years) | 0.801 (0.241–2.660) | 0.717 | 1.650 (0.683–3.960) | 0.267 |
| B symptoms (abscent vs present) | 0.307 (0.0917–1.0200) | 0.0538 | 0.246 (0.0971–0.621) | 0.00294 |
| Extranodal lesions (abscent vs present) | 0.167 (0.0538–0.5210) | 0.00201 | 0.275 (0.109–0.694) | 0.00644 |
| Clinical stage (I + II vs III + IV) | 0.199 (0.0538–0.7360) | 0.0155 | 0.321 (0.128–0.805) | 0.0155 |
| serum LDH (normal vs elevated) | 0.105 (0.0135–0.8100) | 0.0306 | 0.507 (0.195–1.320) | 0.164 |
| PI score (0–2 vs 3–5) | 0.128 (0.0345–0.4720) | 0.00204 | 0.291 (0.120–0.704) | 0.00615 |
| sIL-2R (normal vs elevated) | NA | NA | 0.433 (0.101–1.870) | 0.262 |
| Pathological factors | ||||
| Hans' criteria (GCB vs non-GCB) | 1.954 (0.588–6.490) | 0.274 | 0.808 (0.335–1.950) | 0.636 |
| MIB-1 index (<90% vs ≥90%) | 0.377 (0.115–1.230) | 0.107 | 0.501 (0.197–1.270) | 0.146 |
| MUM1 expression (negative vs positive) | 0.490 (0.148–1.629) | 0.244 | 0.809 (0.335–1.950) | 0.638 |
| BCL2 expression (negative vs positive) | 0.840 (0.227–3.100) | 0.791 | 1.030 (0.394–2.670) | 0.956 |
| BACH2 expression levels (low vs high) | 0.209 (0.0458–0.9540) | 0.0433 | 0.422 (0.162–1.100) | 0.0769 |
| MYC expression level (low vs high) | 0.184 (0.0403–0.8430) | 0.0293 | 0.563 (0.230–1.380) | 0.209 |
CI, confidential interval; HR, hazard ratio; IPI, international prognostic index; LDH, lactate dehydrogenase; OS, overall survival; PFS, progression-free survival; sIL-2R, soluble inteleukin-2 receptor. NA, this cannot be calculated because no patients with normal sIL-2R died.